» Articles » PMID: 15685717

Investigating Heterogeneity in an Individual Patient Data Meta-analysis of Time to Event Outcomes

Overview
Journal Stat Med
Publisher Wiley
Specialty Public Health
Date 2005 Feb 3
PMID 15685717
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Differences across studies in terms of design features and methodology, clinical procedures, and patient characteristics, are factors that can contribute to variability in the treatment effect between studies in a meta-analysis (statistical heterogeneity). Regression modelling can be used to examine relationships between treatment effect and covariates with the aim of explaining the variability in terms of clinical, methodological, or other factors. Such an investigation can be undertaken using aggregate data or individual patient data. An aggregate data approach can be problematic as sufficient data are rarely available and translating aggregate effects to individual patients can often be misleading. An individual patient data approach, although usually more resource demanding, allows a more thorough investigation of potential sources of heterogeneity and enables a fuller analysis of time to event outcomes in meta-analysis. Hierarchical Cox regression models are used to identify and explore the evidence for heterogeneity in meta-analysis and examine the relationship between covariates and censored failure time data in this context. Alternative formulations of the model are possible and illustrated using individual patient data from a meta-analysis of five randomized controlled trials which compare two drugs for the treatment of epilepsy. The models are further applied to simulated data examples in which the degree of heterogeneity and magnitude of treatment effect are varied. The behaviour of each model in each situation is explored and compared.

Citing Articles

Pharmacokinetic analysis across studies to drive knowledge-integration: A tutorial on individual patient data meta-analysis (IPDMA).

Van Wijk R, Imperial M, Savic R, P Solans B CPT Pharmacometrics Syst Pharmacol. 2023; 12(9):1187-1200.

PMID: 37303132 PMC: 10508576. DOI: 10.1002/psp4.13002.


CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data.

Karamouza E, Glasspool R, Kelly C, Lewsley L, Carty K, Kristensen G Cancers (Basel). 2023; 15(6).

PMID: 36980708 PMC: 10047009. DOI: 10.3390/cancers15061823.


Radiotherapy Fraction in Limited-Stage Small Cell Lung Cancer in the Modern Era: A Systematic Review and Meta-Analysis of 8006 Reconstructed Individual Patient Data.

Zhao J, Wu L, Hu C, Bi N, Wang L Cancers (Basel). 2023; 15(1).

PMID: 36612272 PMC: 9818135. DOI: 10.3390/cancers15010277.


Transportability Methods for Time-to-Event Outcomes: Application in Adjuvant Colon Cancer Trials.

Zuo S, Josey K, Raghavan S, Yang F, Juarez-Colunga E, Ghosh D JCO Clin Cancer Inform. 2022; 6:e2200088.

PMID: 36516368 PMC: 10166520. DOI: 10.1200/CCI.22.00088.


Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis.

Tan D, Ng C, Tay P, Syn N, Muthiah M, Lim W JAMA Netw Open. 2022; 5(6):e2219407.

PMID: 35767258 PMC: 9244612. DOI: 10.1001/jamanetworkopen.2022.19407.